Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney, liver, and metabolic diseases. The company's key focus is the development of its investigational product candidate, sparsentan. This novel therapy is in late-stage development for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can lead to end-stage kidney disease.
Travere Therapeutics has made significant strides in its mission, marked by several recent achievements. The company reported positive topline data from the pivotal phase-III PROTECT study of sparsentan in IgAN, showing a substantial reduction in proteinuria and potential long-term benefits in preserving kidney function. This led to the conditional marketing authorization of sparsentan under the brand name FILSPARI® in Europe and anticipated full approval in the U.S.
Additionally, Travere Therapeutics is advancing other innovative therapies. The company is exploring the potential of pegtibatinase as the first disease-modifying treatment for classical homocystinuria (HCU), with topline data expected in 2026.
Travere's strategic partnerships, such as with CSL Vifor, amplify its reach and impact. CSL Vifor has exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand. Together, these companies are dedicated to bringing promising treatments to patients worldwide.
The company's financial condition remains robust, supported by a strong pipeline and successful trials. Travere's commitment to the rare disease community is evidenced by its relentless pursuit of better treatment options and its collaborative efforts with patients, families, and caregivers.
Travere Therapeutics (NASDAQ: TVTX) provided a regulatory update on its sparsentan program for focal segmental glomerulosclerosis (FSGS). Following successful interim results from the Phase 3 DUPLEX Study, the FDA indicated that the data was insufficient for accelerated approval this year. The company remains optimistic about future submissions pending additional data expected in 2022. Meanwhile, initial discussions with the EMA supported a conditional marketing authorization submission planned for late 2021. Results from the confirmatory endpoint are anticipated in 2023.
Travere Therapeutics (TVTX) reported first-quarter 2021 financial results, highlighting net product sales of $47.4 million, slightly down from $47.8 million YoY. The company achieved a significant milestone by completing the interim endpoint in the DUPLEX Study of sparsentan for FSGS and is pursuing accelerated approval from regulators. The PROTECT Study for IgA nephropathy is nearing full enrollment, with topline data expected in Q3 2021. Cash and equivalents stood at $520.9 million as of March 31, 2021. Despite increased R&D and SG&A expenses, the company remains optimistic about future growth.
Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube, Ph.D., will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 5:00 p.m. ET. A live webcast of the presentation will be available on the company's investor relations page and an archived replay will be accessible for 30 days thereafter.
The company is dedicated to addressing the urgent treatment needs of patients with rare diseases and aims to deliver impactful therapies in collaboration with the rare disease community.
Travere Therapeutics (NASDAQ: TVTX) will announce its Q1 2021 financial results on May 6, 2021, after U.S. market close. A conference call is scheduled for the same day at 4:30 p.m. ET, aimed at discussing the results and providing a business update. Interested participants can join via dial-in or a live webcast on Travere's investor relations site. A replay will be accessible from 7:30 p.m. ET on May 6 to 7:30 p.m. ET on May 13.
Travere Therapeutics (TVTX) announced strong performance in its fourth quarter and full year 2020 financial results, with net product sales increasing by 13% year-over-year to $198 million. The company reported a net loss of $121.6 million for Q4 2020, compared to $30.3 million in Q4 2019. Key developments include achieving the interim endpoint in the DUPLEX Study for FSGS and plans to report data from the PROTECT Study for IgAN in Q3 2021. The company’s cash position stands at $361.6 million, boosted by a recent stock offering generating $189 million in proceeds.
Travere Therapeutics (NASDAQ: TVTX) participates in Rare Disease Day 2021, honoring over 400 million individuals worldwide affected by rare diseases. CEO Eric Dube emphasizes their commitment to improving patient outcomes and community access to treatment. The company supports various organizations tackling healthcare inequities and promoting innovation in rare diseases. The National Burden of Rare Disease Study, expected to release economic impact findings on February 25, aims to raise awareness and inform policy changes. Travere will host an internal event on February 26 to celebrate this initiative.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming virtual investor conferences. The first is the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 1:00 p.m. ET. The second is the Barclays Global Healthcare Conference on March 10, 2021, at 11:30 a.m. ET. Live webcasts and archived replays will be available for 30 days on their website. Travere focuses on developing therapies for rare diseases, engaging with the community to understand their needs and deliver impactful treatments.
Travere Therapeutics (NASDAQ: TVTX) has received orphan designation from the European Commission for sparsentan, targeting IgA nephropathy (IgAN), a rare kidney disorder that can lead to end-stage kidney disease. Sparsentan, currently in pivotal Phase 3 trials for both IgAN and focal segmental glomerulosclerosis (FSGS), achieved its interim proteinuria endpoint in the DUPLEX Study. The company aims to set a new treatment standard for IgAN and indicates positive early results. Orphan designation grants a 10-year marketing exclusivity and various incentives in the EU.
Travere Therapeutics has completed an underwritten public offering of 7,532,500 shares of its common stock at $26.75 per share, raising approximately $201.5 million in gross proceeds. The offering included 982,500 shares from the full exercise of underwriters’ options. The shares were sold under an effective shelf registration statement filed with the SEC. The offering was managed by BofA Securities, Jefferies, and SVB Leerink.
Travere Therapeutics (NASDAQ: TVTX) will announce its fourth quarter and full year 2020 financial results on March 1, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The call can be accessed via dial-in or live webcast, with a replay available for a week post-call. Travere is focused on developing therapies for rare diseases, emphasizing its commitment to patient needs and insights.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
What is the primary focus of Travere Therapeutics?
What is sparsentan?
What recent achievements has Travere Therapeutics made?
What are the indications for FILSPARI®?
Who are Travere Therapeutics' strategic partners?
What is the potential significance of pegtibatinase?
What are the key safety considerations for FILSPARI® therapy?
What is the financial condition of Travere Therapeutics?
How does Travere Therapeutics develop its therapies?
Where can more information about Travere Therapeutics be found?
